| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f5bb368b03cfa08cf0c3c4fa488ad70 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 |
| filingDate |
2011-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd0c91ff434c8e632fafd804a7555e95 |
| publicationDate |
2011-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011207759-A1 |
| titleOfInvention |
Method for treatment of atherosclerotic disease |
| abstract |
A method of effecting regression of atherosclerotic disease in a patient whose plasma lipid concentrations are at levels considered normal or optimal. The method involves treating the patient with a combination of a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor and niacin. Disease regression has been observed over periods as short as 14 months, preferably 8 months. |
| priorityDate |
2010-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |